SCHEMBL4857477

SCHEMBL4857477

COc1cc(-c2ccc3c(c2)Nc2ccc(CCO)cc2NC3=O)ccc1C(N)=O

nearest known ligand 0.74

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 19/20 0.74
AURKA O14965 1/20 0.51
KDR P35968 1/20 0.51
AURKB Q96GD4 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4858793 0.89 CHEK1 (0.72) CHEK1AURKB
SCHEMBL4858978 0.85 CHEK1 (1.00) CHEK1KDRAURKB
SCHEMBL4856845 0.85 CHEK1 (0.70) CHEK1AURKAKDRAURKB
SCHEMBL4857711 0.83 CHEK1 (0.62) CHEK1
SCHEMBL4859066 0.81 CHEK1 (0.79) CHEK1
SCHEMBL4855590 0.80 CHEK1 (0.64) CHEK1AURKAKDRAURKB
SCHEMBL6827304 0.80 CHEK1 (0.71) CHEK1AURKB
SCHEMBL4852852 0.80 CHEK1 (0.72) CHEK1KDRAURKB
SCHEMBL16712597 0.80 CHEK1 (0.61) CHEK1AURKB
SCHEMBL4848005 0.80 CHEK1 (0.74) CHEK1AURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254867-A1 Heterocyclic Kinase Inhibitors ABBVIE INC. 2007-11-01 US claimed
US-7456169-B2 Heterocyclic kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-11-25 US disclosed
US-20070254867-A1 Heterocyclic Kinase Inhibitors ABBVIE INC. 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254867-A1 Heterocyclic Kinase Inhibitors MAP3K20, MAP3K19, MAP4K2 CHEK1 38/4885AURKA 268/4885KDR 819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.